The Manufacturers Life Insurance Company Buys 870 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

The Manufacturers Life Insurance Company boosted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 5.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,816 shares of the company’s stock after purchasing an additional 870 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.05% of TransMedics Group worth $2,683,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its position in TransMedics Group by 10.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company’s stock valued at $31,358,000 after purchasing an additional 38,951 shares in the last quarter. Vanguard Group Inc. boosted its holdings in TransMedics Group by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock worth $147,214,000 after acquiring an additional 50,673 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in TransMedics Group in the second quarter worth about $1,400,000. Russell Investments Group Ltd. boosted its holdings in TransMedics Group by 337,462.5% in the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock worth $1,997,000 after acquiring an additional 26,997 shares in the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in TransMedics Group in the first quarter worth about $1,588,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Up 3.0 %

Shares of TMDX stock opened at $138.12 on Wednesday. The stock has a 50 day moving average of $155.92 and a 200 day moving average of $134.97. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.14. The company had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. TransMedics Group’s quarterly revenue was up 117.7% on a year-over-year basis. During the same period last year, the business earned ($0.03) earnings per share. On average, equities research analysts expect that TransMedics Group, Inc. will post 1.22 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Oppenheimer raised their price target on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Robert W. Baird assumed coverage on TransMedics Group in a report on Tuesday, September 24th. They issued an “outperform” rating and a $200.00 price target for the company. Morgan Stanley raised their price target on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Stephens raised their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, Piper Sandler restated an “overweight” rating and issued a $180.00 price objective on shares of TransMedics Group in a research note on Monday. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $174.30.

Insider Activity

In other news, Director James R. Tobin sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $159.33, for a total value of $3,186,600.00. Following the completion of the sale, the director now directly owns 173,146 shares in the company, valued at $27,587,352.18. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at $3,089,766.32. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director James R. Tobin sold 20,000 shares of TransMedics Group stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $159.33, for a total value of $3,186,600.00. Following the completion of the sale, the director now directly owns 173,146 shares in the company, valued at $27,587,352.18. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,205 shares of company stock worth $10,089,374 over the last three months. 7.00% of the stock is currently owned by corporate insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.